Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women

Esther M. Brooks-Asplund, Carrie E. Tupper, Jane M. Daun, W. Larry Kenney, Joseph Gerard Cannon

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Hormone replacement therapy (HRT) reduces the risk for osteoporosis but transiently increases cardiovascular risk for some postmenopausal women. This study investigated the hypothesis that these risks are associated with HRT-induced changes in mononuclear cell secretion of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and associated soluble receptors. Compared to the untreated condition (n=8), estrogen therapy (n=7) and estrogen+progestin therapy (n=7) both caused 2-fold elevations in TNF-α secretion. IL-6 secretion was increased (48%, P=0.04) only by estrogen+progestin therapy. Although soluble receptor secretion was not different among groups, soluble TNF receptor type I and IL-6 receptor secretion were inversely related to plasma follicle stimulating hormone (P<0.05). Both therapies reduced plasma osteocalcin (a marker for osteoporosis) by ∼50% (P<0.002). Plasma C-reactive protein (CRP, a marker for cardiovascular risk) was 3-fold higher in women receiving only estrogen, compared to untreated women (P=0.01), and twice as high as those receiving estrogen+progestin (P=0.045). Simple linear relationships were not observed between cytokine secretion and these markers, but a significant HRT/TNF-α interaction with osteocalcin (P=0.022) and an HRT/IL-6 interaction with CRP (P=0.016) indicated more complex relationships between hormone replacement, cytokine activity, and health risks associated with menopause.

Original languageEnglish (US)
Pages (from-to)193-200
Number of pages8
JournalCytokine
Volume19
Issue number4
DOIs
StatePublished - Jan 1 2002

Fingerprint

Tumor Necrosis Factor Receptors
Hormone Replacement Therapy
Interleukin-6
Estrogens
Tumor Necrosis Factor-alpha
Modulation
Hormones
Progestins
Osteocalcin
Plasmas
Osteoporosis
Cytokines
Interleukin-6 Receptors
Health risks
Follicle Stimulating Hormone
Therapeutics
Menopause
C-Reactive Protein
Blood Proteins
Health

Keywords

  • Bone turnover
  • C-reactive protein
  • Estrogen
  • FSH
  • Progestin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Hematology
  • Molecular Biology

Cite this

Brooks-Asplund, E. M., Tupper, C. E., Daun, J. M., Kenney, W. L., & Cannon, J. G. (2002). Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. Cytokine, 19(4), 193-200. https://doi.org/10.1006/cyto.2002.1963

Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. / Brooks-Asplund, Esther M.; Tupper, Carrie E.; Daun, Jane M.; Kenney, W. Larry; Cannon, Joseph Gerard.

In: Cytokine, Vol. 19, No. 4, 01.01.2002, p. 193-200.

Research output: Contribution to journalArticle

Brooks-Asplund, Esther M. ; Tupper, Carrie E. ; Daun, Jane M. ; Kenney, W. Larry ; Cannon, Joseph Gerard. / Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. In: Cytokine. 2002 ; Vol. 19, No. 4. pp. 193-200.
@article{f9b7ead660a543e1a5e525616a8cca1e,
title = "Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women",
abstract = "Hormone replacement therapy (HRT) reduces the risk for osteoporosis but transiently increases cardiovascular risk for some postmenopausal women. This study investigated the hypothesis that these risks are associated with HRT-induced changes in mononuclear cell secretion of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and associated soluble receptors. Compared to the untreated condition (n=8), estrogen therapy (n=7) and estrogen+progestin therapy (n=7) both caused 2-fold elevations in TNF-α secretion. IL-6 secretion was increased (48{\%}, P=0.04) only by estrogen+progestin therapy. Although soluble receptor secretion was not different among groups, soluble TNF receptor type I and IL-6 receptor secretion were inversely related to plasma follicle stimulating hormone (P<0.05). Both therapies reduced plasma osteocalcin (a marker for osteoporosis) by ∼50{\%} (P<0.002). Plasma C-reactive protein (CRP, a marker for cardiovascular risk) was 3-fold higher in women receiving only estrogen, compared to untreated women (P=0.01), and twice as high as those receiving estrogen+progestin (P=0.045). Simple linear relationships were not observed between cytokine secretion and these markers, but a significant HRT/TNF-α interaction with osteocalcin (P=0.022) and an HRT/IL-6 interaction with CRP (P=0.016) indicated more complex relationships between hormone replacement, cytokine activity, and health risks associated with menopause.",
keywords = "Bone turnover, C-reactive protein, Estrogen, FSH, Progestin",
author = "Brooks-Asplund, {Esther M.} and Tupper, {Carrie E.} and Daun, {Jane M.} and Kenney, {W. Larry} and Cannon, {Joseph Gerard}",
year = "2002",
month = "1",
day = "1",
doi = "10.1006/cyto.2002.1963",
language = "English (US)",
volume = "19",
pages = "193--200",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women

AU - Brooks-Asplund, Esther M.

AU - Tupper, Carrie E.

AU - Daun, Jane M.

AU - Kenney, W. Larry

AU - Cannon, Joseph Gerard

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Hormone replacement therapy (HRT) reduces the risk for osteoporosis but transiently increases cardiovascular risk for some postmenopausal women. This study investigated the hypothesis that these risks are associated with HRT-induced changes in mononuclear cell secretion of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and associated soluble receptors. Compared to the untreated condition (n=8), estrogen therapy (n=7) and estrogen+progestin therapy (n=7) both caused 2-fold elevations in TNF-α secretion. IL-6 secretion was increased (48%, P=0.04) only by estrogen+progestin therapy. Although soluble receptor secretion was not different among groups, soluble TNF receptor type I and IL-6 receptor secretion were inversely related to plasma follicle stimulating hormone (P<0.05). Both therapies reduced plasma osteocalcin (a marker for osteoporosis) by ∼50% (P<0.002). Plasma C-reactive protein (CRP, a marker for cardiovascular risk) was 3-fold higher in women receiving only estrogen, compared to untreated women (P=0.01), and twice as high as those receiving estrogen+progestin (P=0.045). Simple linear relationships were not observed between cytokine secretion and these markers, but a significant HRT/TNF-α interaction with osteocalcin (P=0.022) and an HRT/IL-6 interaction with CRP (P=0.016) indicated more complex relationships between hormone replacement, cytokine activity, and health risks associated with menopause.

AB - Hormone replacement therapy (HRT) reduces the risk for osteoporosis but transiently increases cardiovascular risk for some postmenopausal women. This study investigated the hypothesis that these risks are associated with HRT-induced changes in mononuclear cell secretion of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and associated soluble receptors. Compared to the untreated condition (n=8), estrogen therapy (n=7) and estrogen+progestin therapy (n=7) both caused 2-fold elevations in TNF-α secretion. IL-6 secretion was increased (48%, P=0.04) only by estrogen+progestin therapy. Although soluble receptor secretion was not different among groups, soluble TNF receptor type I and IL-6 receptor secretion were inversely related to plasma follicle stimulating hormone (P<0.05). Both therapies reduced plasma osteocalcin (a marker for osteoporosis) by ∼50% (P<0.002). Plasma C-reactive protein (CRP, a marker for cardiovascular risk) was 3-fold higher in women receiving only estrogen, compared to untreated women (P=0.01), and twice as high as those receiving estrogen+progestin (P=0.045). Simple linear relationships were not observed between cytokine secretion and these markers, but a significant HRT/TNF-α interaction with osteocalcin (P=0.022) and an HRT/IL-6 interaction with CRP (P=0.016) indicated more complex relationships between hormone replacement, cytokine activity, and health risks associated with menopause.

KW - Bone turnover

KW - C-reactive protein

KW - Estrogen

KW - FSH

KW - Progestin

UR - http://www.scopus.com/inward/record.url?scp=0036387156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036387156&partnerID=8YFLogxK

U2 - 10.1006/cyto.2002.1963

DO - 10.1006/cyto.2002.1963

M3 - Article

VL - 19

SP - 193

EP - 200

JO - Cytokine

JF - Cytokine

SN - 1043-4666

IS - 4

ER -